[1]王沛坚 陈威 董徽 马为.中国自主研发RDN器械治疗高血压临床试验数据的特色[J].心血管病学进展,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
　WANG Peijian,CHEN Wei,DONG Hui,et al.Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China[J].Advances in Cardiovascular Diseases,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
点击复制

中国自主研发RDN器械治疗高血压临床试验数据的特色()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年10期
页码:
880
栏目:
约稿
出版日期:
2024-10-25

文章信息/Info

Title:
Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China
作者:
王沛坚1 陈威 2 董徽 3 马为4; 5
(1.成都医学院第一附属医院心血管内科;四川成都 610500;2. 福建医科大学省立临床学院,福州大学省立医院心血管内科;福建福州 350013;3. 中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院心血管内科;北京 100037;4. 北京大学第一医院心血管内科;北京100034;5. 北京大学第一医院心血管疾病研究所 超声心动图中心实验室;北京100034)
Author(s):
WANG Peijian1; CHEN Wei2; DONG Hui3; MA Wei4; 5
(1. Department of Cardiology,The First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,Sichuan,China2. Provincial Clinical Medicine College of Fujian Medical University, Department of Cardiology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial HospitalFuzhou, 350001, China3. Department of Cardiology, National Center for Cardiovascular Diseases and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China4. Department of Cardiology,Peking University First Hospital,Beijing 100034,China5. Echocardiography Center Laboratory,Cardiovascular Disease Research Institute,Peking University First Hospital,Beijing 100034,China)
关键词:
高血压; 去肾神经术; 降压治疗
Keywords:
Hypertension; Renal denervation; Antihypertensive therapy
DOI:
10.16806/j.cnki.issn.1004-3934.2024.10.004
摘要:
经皮去肾神经术（RDN）是继治疗性生活方式改善以及药物治疗之外的第三种降压手段。目前，国内已经完成了三项RDN临床研究，Iberis-HTN研究、Netrod-HTN研究以及SMART研究。三项研究均入选了未控制的高血压人群，进行射频RDN治疗，分别采用6个月时的24 h动态血压、诊室收缩压和复合终点(包括诊室收缩压达标率< 140 mmHg)以及抗高血压药物负荷指数作为重要终点。初步证明了国人进行RDN治疗的有效性和安全性。三项研究也显示了中国特色。在器械设计方面，无论是Iberis?多电极肾动脉射频消融导管具有经桡动脉路径行RDN的功能，还是SyMapCath??导管具备肾神经标测/选择性消融的特点以及Netrod?网状多电极肾动脉射频消融导管都与国外设计有所不同。国内临床研究设计所提出的药物负荷指数方法也逐渐被认可。期待进一步开展RDN的基础、临床研究，促进高血压以及相关疾病的治疗。
Abstract:
Renal denervation (RDN) is the third method of antihypertension in addition to therapeutic lifestyle improvement and medication. At present,three RDN clinical studies (Iberis-HTN study,Netrod-HTN study and SMART study) have been completed in China. All three studies enrolled uncontrolled hypertension patients for radiofrequency RDN treatment. 24-hour ambulatory blood pressure,office systolic blood pressure,and composite endpoints including office systolic blood pressure control rate (<140 mmHg) and antihypertensive drug composite index at 6 months were used as primary endpoints,respectively. The efficacy and safety of RDN in Chinese were preliminarily proved. Three studies also show Chinese characteristics. In terms of device design,Iberis? multi-electrode renal artery radiofrequency ablation catheter has the function of RDN via radial artery route . SyMapCath ?? catheter has the characteristics of msRDN and Netrod? multi-electrode renal artery radiofrequency ablation catheter is different from foreign designs. The antihypertensive drug composite index proposed in domestic clinical trial is recognized by other trials. We look forward to further basic and clinical RDN research to promote the treatment of hypertension and related diseases.

参考文献/References:

[1] 席朝军. 健康人群及高血压和糖尿病患者的臂间血压差异研究[D]. 江苏:苏州大学,2016.

[2] 中国老年医学学会高血压分会,北京高血压防治协会,国家老年疾病临床医学研究中心,等. 中国老年高血压管理指南2023[J]. 中华高血压杂志,2023,31(6):508-538.

[3] Mahfoud F,Kandzari DE,Kario K,et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED):a randomised,sham-controlled trial[J]. Lancet,2022,399(10333):1401-1410.

[4] Fengler K,Rommel KP,Kriese W,et al. 6- and 12-month follow-up from a?randomized clinical trial?of?ultrasound vs radiofrequency renal?denervation (RADIOSOUND-HTN)[J]. JACC Cardiovasc Interv,2023,16(3):367-369.

[5] Ji M,Chen H,Shen L,et al. Validation of a novel renal denervation system with cryoablation:a preclinical study and case series[J]. JACC Basic Transl Sci,2022,7(2):101-112.

[6] Pathak A,Rudolph UM,Saxena M,et al. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications[J]. EuroIntervention,2023,19(7):602-611.

[7] 李敏,范芳芳,张岩,等. 肾交感神经消融术治疗高血压的有效性及安全性荟萃分析[J]. 中国介入心脏病学杂志,2021,29(7):391-402.

[8] Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension:Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens,2023,41(12):1874-2071.

[9] 李月平,卢成志,蒋雄京,等. 经皮去肾神经术治疗高血压中国专家科学声明[J]. 中国介入心脏病学杂志,2023,31(12):881-893.

[10] Wang J,Yin Y,Lu C,et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART):6-month follow-up of a randomised,controlled trial[J]. EClinicalMedicine,2024,72:102626.

[11] de Champlain J,Karas M,Nguyen P,et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients[J]. J Hypertens,1998,16(11):1357-1369.

[12] Leenen FH,Myers MG,Joyner CD,et al. Differential effects of once-daily antihypertensive drugs on blood pressure,left ventricular mass and sympathetic activity:Nifedipine-GITS versus felodipine-ER versus enalapril[J]. Can J C ardiol,2002,18(12):1285-1293.

[13] Khalid N,Rogers T,Shlofmitz E,et al. Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension[J]. Cardiovasc R evasc M ed,2019,20(10):891-896.

[14] Barbato E,Azizi M,Schmieder RE,et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur H eart J,2023,44(15):1313-1330.

[15] Ettehad D,Emdin CA,Kiran A,et al. Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis[J]. Lancet,2016,387(10022):957-967.

[16] Kario K,Kim BK,Aoki J,et al. Renal denervation in Asia:consensus statement of the Asia Renal Denervation Consortium[J]. Hypertension,2020,75(3):590-602.

[17] Fudim M,Sobotka AA,Yin YH,et al. Selective vs. global renal denervation:a case for less is more[J]. Curr Hypertens Rep,2018,20(5):37.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
　SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
　FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
　CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
　ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
　ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
　HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
　ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
　LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
　WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]李昱熙 张震 余静 蒋雄京.去肾神经治疗高血压的临床前景和探索方向[J].心血管病学进展,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
　LI YuxiZHANG ZhenYU JingJIANG Xiongjing.Future of Renal Denervation on Hypertension Therapy[J].Advances in Cardiovascular Diseases,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
[12]陈晓平,左祥浩,叶涛,等.当前经导管去肾神经术治疗高血压面临的挑战[J].心血管病学进展,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
　CHEN Xiaoping,ZUO Xianghao,YE Tao,et al.Current Challenges of Transcatheter Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
[13]亢园园 罗淞元 许建忠 罗建方 卢成志.当前不同去肾神经术的特点和存在的问题[J].心血管病学进展,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
　KANG yuanyuan,LUO Songyuan,XU Jianzhong,et al.The Mechanisms and Future Challenges of Different Renal Denervation Therapy[J].Advances in Cardiovascular Diseases,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
[14]封欣妤 张冬颖 邹玉宝 冯颖青 程康.如何选择去肾神经术治疗高血压的最适宜人群[J].心血管病学进展,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
　FENG Xinyu,ZHANG Dongying,ZOU Yubao,et al.How to Select the Optimal Population for Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
[15]董一飞 张毅 李燕 贾楠.经皮去肾神经术治疗高血压的临床获益：证据和争议[J].心血管病学进展,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]
　DONG Yifei,ZHANG Yi,LI Yan,et al.Clinical Benefit of Renal Denervation In the Treatment of Hypertension:Evidence And Controversy[J].Advances in Cardiovascular Diseases,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]

更新日期/Last Update: 2024-11-01